During Tuesday’s Morning trade, Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), gained 1.67% to $1.83.
Advanced Micro Devices, declared a partnership with Oculus and Dell to equip Oculus Ready PCs with AMD Radeon GPUs, starting at $999USD. The powerful PCs are designed to deliver stunning gaming performance and enable spectacular VR experiences for consumers around the world by leveraging AMD VR leadership with LiquidVR™ and Graphics Core Next architecture.
In March, AMD declared an initiative to deliver the ultimate VR experience for developers and users enabled through AMD LiquidVR™ technology. AMD LiquidVR™ enables low-latency VR performance that maintains reliable comfort during your VR experience, and plug-and-play compatibility with VR headsets. AMD GPU software and hardware subsystems are a major component in making AMD LiquidVR™ a reality and in turn allowing for developers and content creators to enable a life-like presence in VR environments.
On other hand, Advanced Micro Devices (AMD)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Group in a report issued on Friday, MarketBeat.com reports. They presently have a $3.50 price objective on the semiconductor manufacturer’s stock. Jefferies Group’s price objective points to a potential upside of 101.15% from the company’s previous close.
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
Shares of Best Buy Co Inc (NYSE:BBY), declined -1.27% to $37.21, during its current trading session.
Best Buy Co., Inc. declared the appointment of Karen McLoughlin to its Board of Directors. McLoughlin is the chief financial officer at Cognizant Technology Solutions (Nasdaq: CTSH), a Fortune 500 company and leading provider of information technology, business process and consulting services.
McLoughlin, 50, joined Cognizant in 2003 and has spearheaded several critical transformation initiatives during her time with the company. She has been the chief financial officer since 2012, overseeing the company’s worldwide accounting and controllership, enterprise risk administration, financial planning and analysis, internal audit, investor relations, tax and treasury functions.
On other hand, Best Buy Co (BBY)‘s stock had its “buy” rating reiterated by research analysts at Bank of America in a report issued on Friday, Analyst Ratings Network.com reports.
The firm also revealed a quarterly dividend, which will be paid on Tuesday, October 6th. Shareholders of record on Tuesday, September 15th will be issued a $0.23 dividend. This represents a $0.92 dividend on an annualized basis and a yield of 2.44%. The ex-dividend date is Friday, September 11th.
Best Buy Co., Inc. operates as a retailer of technology products, services, and solutions in the United States and internationally. Its stores offer consumer electronics comprising primarily of television and home theaters; digital cameras and camcorders; DVD and Blu-ray players; portable electronics, such as MP3 devices, headphones and speakers, car stereo, navigation and satellite radio; and related accessories.
Shares of Alamos Gold, Inc. (NYSE:AGI), dipped -1.11%, and is now trading at $2.67.
Alamos Gold Inc., planned to release its third quarter 2015 financial results before the start of trading on Thursday, November 12, 2015. Senior administration will host a conference call at 12:00 pm ET on that day to discuss the results.
On other hand, Shares of Alamos Gold (AGI) have received an average rating of “Buy” from the eleven research firms that are covering the stock, MarketBeat.Com reports. Four equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $6.75.
Alamos Gold, Inc. operates as an intermediate gold producer primarily in North America. The company primarily holds a 100% interest in the Young-Davidson gold mine, which comprises mineral leases and claims totaling 11,000 acres in Northern Ontario, Canada.
Finally, Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), lost -1.73%, and is now trading at $160.64.
Valeant Pharmaceuticals International, declared that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) with respect to the formerly declared tender offer by its indirect wholly owned partner, Blue Partner Corp., for all of the outstanding shares of common stock of Synergetics USA, Inc. (SURG) (“Synergetics”) at a price per share of $6.50, net to the holder in cash (less any applicable withholding taxes and without interest), plus one contractual contingent value right per share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash (less any applicable withholding taxes and without interest) was granted early termination, effective October 5, 2015, by the U.S. Federal Trade Commission. The waiting period was planned to expire at 11:59 p.m., New York City time on October 7, 2015. The early termination of the HSR waiting period satisfies one of the conditions to consummate the tender offer. The completion of the tender offer remains subject to certain other conditions as described in the Tender Offer Statement on Plan TO filed by Valeant on September 16, 2015, as amended. Subject to the satisfaction of the other conditions to closing, the transaction is predictable to close in the fourth quarter of 2015.
On other hand, Shares of Valeant Pharmaceuticals Intl (VRX) have been assigned an average recommendation of “Buy” from the twenty-seven brokerages that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and twenty-one have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $240.35.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
